A renal resistive index (RRI) of ≥0.8 was associated with an increased risk of cardiovascular (CV) events in ASCVD* patients with preserved ejection fraction (EF) but not in those with mid-range or reduced EF, according to a study presented at ESC Asia 2019.
Among Asian patients with heart failure (HF), those who have HFpEF* with a lean diabetic phenotype have the worst prognosis among the five phenotypes identified in Asians which include patients with HFrEF**, according to data from the Asian-HF registry presented at the ESC Asia Congress 2019.
Coronary artery bypass grafting (CABG) reduces the risk nonfatal myocardial infarction (MI) and major adverse cardiovascular events (MACE) among diabetes mellitus (DM) patients with multivessel disease (MVD), according to a recent study presented at the Asia Congress of the European Society of Cardiology (ESC Asia 2019).
Treatment options for patients with heart failure with preserved ejection fraction (HFpEF) remain limited, with benefits that are marginal at best, according to Prof Michel Komajda, past president of the European Society of Cardiology (ESC), at their recently concluded 2019 Asia Congress (ESC Asia 2019).
Showing patients a short video about coronary angiography or angioplasty helps improve knowledge about the procedure and consequently alleviate their anxiety, according to a study presented at the European Society of Cardiology (ESC) Asia Congress 2019 with Asian Pacific Society of Cardiology (APSC) and the Asean Federation of Cardiology (AFC).
Mindfulness-based interventions (MBIs) are beneficial for patients with coronary heart disease (CHD) in reducing perceived stress, depression and anxiety, as shown by evidence in a systematic review, which was presented at the recent European Society of Cardiology (ESC) Asia Congress 2019 in Singapore.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.